1-5 of 5
Carole Estoppey
Close
Sort by
Journal Articles

Integrated Preclinical Data Analysis of ISB 2001 Enables Optimal Starting Dose Selection for a First-in-Class Trispecific T Cell Engager Phase1 Study in Multiple Myeloma

Adam Drake, Maria Pihlgren, Vinu Menon, Daniela Pais, Laura Carretero-Iglesia, Jeremy Berret, Olivia Hall, Julie Macoin, Isabelle Gruber, Elodie Stainnack, Carole Estoppey, Cyrille Dreyfus, Girish Gudi, Tomomi Matsuura, Piet H van der Graft, Michael Dyson, Cyril Konto, Lida Pacaud, Ankita Srivastava, Eugene Zhukovsky, Mario Perro
Journal: Blood
Blood (2023) 142 (Supplement 1): 6574.
https://doi.org/10.1182/blood-2023-181546
Published: 2023
Journal Articles

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma

Blandine Pouleau, Carole Estoppey, Perrine Suere, Emilie Nallet, Amélie Laurendon, Thierry Monney, Daniela Pais Ferreira, Adam Drake, Laura Carretero-Iglesia, Julie Macoin, Jérémy Berret, Maria Pihlgren, Marie-Agnès Doucey, Girish S. Gudi, Vinu Menon, Venkatesha Udupa, Abhishek Maiti, Gautam Borthakur, Ankita Srivastava, Stanislas Blein, M. Lamine Mbow, Thomas Matthes, Zeynep Kaya, Claire M. Edwards, James R. Edwards, Emmanuelle Menoret, Charlotte Kervoëlen, Catherine Pellat-Deceunynck, Philippe Moreau, Eugene Zhukovsky, Mario Perro, Myriam Chimen
Journal: Blood
Blood (2023) 142 (3): 260–273.
https://doi.org/10.1182/blood.2022019451
Published: 2023
Includes: Supplemental data
Journal Articles

Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL

Sammicheli Stefano, Camille Grandclement, Valentina Labanca, Stefania De Angelis, Carole Estoppey, Myriam Chimen, Blandine Pouleau, Perrine Suere, Emilie Nallet, Ankita Srivastava, Eric J. Feldman, Igor Proscurshim, Cyril Konto, Eugene Zhukovsky, Mario Perro
Journal: Blood
Blood (2022) 140 (Supplement 1): 6237–6238.
https://doi.org/10.1182/blood-2022-162201
Published: 2022
Journal Articles

ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens

Maria Pihlgren, Olivia Hall, Laura Carretero, Carole Estoppey, Adam Drake, Daniela Pais, Jeremy Loyau, Jeremy Berret, Isabelle Gruber, Perrine Suere, Vincent Schnorhk, Emilie Nallet, Blandine Pouleau, Myriam Chimen, Julie Macoin, Elodie Stainnack, Thierry Monney, Aurore Delachat, Cyrille Dreyfus, Thomas Matthes, Cyril Konto, Michael Dyson, Stanislas Blein, Lamine Mbow, Rebecca Wood, Ankita Srivastava, Eugene Zhukovsky, Mario Perro
Journal: Blood
Blood (2022) 140 (Supplement 1): 858–859.
https://doi.org/10.1182/blood-2022-159353
Published: 2022
Journal Articles

ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma

Sammicheli Stefano, Camille Grandclement, Elie Dehilly, Maria Panagopoulou, Evangelia Martini, Rosa Castillo, Perrine Suere, Blandine Pouleau, Carole Estoppey, Julia Frei, Jeremy Loyau, Thierry Monney, Rebecca Wood, Amelie Croset, Alain Rubod, Girish Gudi, Venkatesha Udupa, Sunitha Gn, Vinu Menon, Daniel Rasmussen, Jeppe Koch Olsen, Roberto Giovannini, Aravind Chakrapani, Stanislas Blein, Marie-Agnes Doucey, Adam Drake, Alessandro Riva, Cyril Konto, Mario Perro, Lamine Mbow
Journal: Blood
Blood (2021) 138 (Supplement 1): 73.
https://doi.org/10.1182/blood-2021-145586
Published: 2021